Adenovirus-Mediated Gene Transfer of Human Vascular Endothelial Growth Factor-D Induces Transient Angiogenic Effects in Mouse Hind Limb Muscle
- 1 March 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 18 (3) , 232-244
- https://doi.org/10.1089/hum.2006.100
Abstract
We evaluated the therapeutic potential of adenovirus (Ad)-mediated human vascular endothelial growth factor-D (hVEGF-D) gene delivery in mice. Hind limbs of hypercholesterolemic mice ( n = 120) were injected with AdhVEGF-D, AdhVEGF-A, control AdLacZ (all at 1×1011viral particles) or saline. Animals were killed at 4, 7, 14, 28, and 42 days. Newly formed vessels were characterized for their quantity, sprouting, angiogenic versus lymphangiogenic phenotype, and arterial versus venous phenotype by endothelial enzymes markers, pericyte coverage, and electron microscopy. Perfusion was measured by power Doppler ultrasound and edema by magnetic resonance imaging (MRI). AdhVEGF-D induced significant formation of new blood vessels, which featured lumenal enlargement, branching, and sprouting. Branching originated mainly from arterioles. The highest vessel density was present on days 4–7 and the effect lasted up to 28 days. Endothelial marker enzyme activity indicated the predominance of arterial capillaries and arterioles. Forty percent of the neovessels were positive for desmin, indicating that VEGF-D increased pericyte coverage. However, branching vessels were highly positive for smooth muscle actin pericyte marker but negative for desmin. Maximal perfusion was measured during the first week after AdhVEGF-D gene transfer. Ultrastructural analysis showed endothelial cells enriched with vesiculo-vacuolar organelles and cytoplasmic protrusions. Modest lymphangiogenic activity was also detected, which could contribute to the relatively low level of edema detected by MRI. In conclusions, AdhVEGF-D has a strong angiogenic effect and a modest lymphangiogenic effect in mouse skeletal muscle. VEGF-D also increases the presence of pericytes/smooth muscle cells in neovessels. AdhVEGF-D is a potential new agent for the induction of therapeutic vascular growth in skeletal muscle.Keywords
This publication has 34 references indexed in Scilit:
- VEGF‐A, VEGF‐D and VEGF‐DΔNΔC induced intimal hyperplasia in carotid arteriesEuropean Journal of Clinical Investigation, 2005
- Gene Transfers of Vascular Endothelial Growth Factor-A, Vascular Endothelial Growth Factor-B, Vascular Endothelial Growth Factor-C, and Vascular Endothelial Growth Factor-D Have No Effects on Atherosclerosis in Hypercholesterolemic Low-Density Lipoprotein-Receptor/Apolipoprotein B48-Deficient MiceCirculation, 2005
- Vascular Endothelial Growth Factor D Is Dispensable for Development of the Lymphatic SystemMolecular and Cellular Biology, 2005
- Gene Therapy for Ischemic Cardiovascular Diseases: Some Lessons Learned from the First Clinical TrialsTrends in Cardiovascular Medicine, 2004
- VEGF‐A promotes tissue repair‐associated lymphatic vessel formation via VEGFR‐2 and the α1β1 and α2β1 integrinsThe FASEB Journal, 2004
- Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor-D Induces Transmural Angiogenesis in Porcine HeartCirculation, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- The Specificity of Receptor Binding by Vascular Endothelial Growth Factor-D Is Different in Mouse and ManJournal of Biological Chemistry, 2001
- Rescue of Diabetes-Related Impairment of Angiogenesis by Intramuscular Gene Therapy with Adeno-VEGFThe American Journal of Pathology, 1999
- Identification of Arterial and Venous Segments of Blood Vessels Using Alkaline Phosphatase Staining of Ink/Gelatin Injected Tissues.Archives of Histology and Cytology, 1998